However, this negative feedback inhibition is disrupted due to dysregulation of the PPP3CB-FOXO3a-miRNA axis in HER2-positive breast cancer resistant to Herceptin (Supplementary Fig. 7f). Here, ERBB2 is linked to breast cancer.